Publications by authors named "Ashwath Gurumurthi"
Article Synopsis
- - Outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) are generally poor; however, the FDA approved Loncastuximab-teserine (Lonca) based on the LOTIS-2 trial results for those who have undergone at least two prior treatments.
- - A retrospective study analyzed 187 patients from 21 US centers treated with Lonca, revealing a complete response rate of 14% and an overall response rate of 32%, indicating lower efficacy in a real-world setting compared to the original trial.
- - Patients in this study had higher risk features, including bulky disease and high-grade B-cell histology, leading to poorer median event-free survival (2.1 months
Background: Rituximab and lenalidomide is a preferred option for relapsed indolent B cell non-Hodgkin lymphoma. Obinutuzumab may be a superior combination partner with lenalidomide given enhanced antibody dependent cellular cytotoxicity and phagocytosis compared to rituximab. Our aim was to determine the recommended phase 2 dose, safety, and activity of lenalidomide in combination with fixed dose of obinutuzumab in relapsed and refractory indolent B cell non-Hodgkin lymphoma.
View Article and Find Full Text PDF